Labile plasma iron levels predict survival in patients with
lower-risk myelodysplastic syndromes

J 2018

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

SWART, L. de, C. REINIERS, T. BAGGULEY, T. van MARREWIJK, D. BOWEN et. al.

Základní údaje

Originální název

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

Autoři

SWART, L. de (528 Nizozemské království), C. REINIERS (528 Nizozemské království), T. BAGGULEY (826 Velká Británie a Severní Irsko), T. van MARREWIJK (528 Nizozemské království), D. BOWEN (826 Velká Británie a Severní Irsko), E. HELLSTROM-LINDBERG (752 Švédsko), A. TATIC (642 Rumunsko), A. SYMEONIDIS (300 Řecko), G. HULS (528 Nizozemské království), J. CERMAK (203 Česká republika), A. A. van de LOOSDRECHT (528 Nizozemské království), H. GARELIUS (752 Švédsko), D. CULLIGAN (826 Velká Británie a Severní Irsko), M. MACHETA (826 Velká Británie a Severní Irsko), M. SPANOUDAKIS (826 Velká Británie a Severní Irsko), P. PANAGIOTIDIS (826 Velká Británie a Severní Irsko), Marta KREJČÍ (203 Česká republika, domácí), N. BLIJLEVENS (528 Nizozemské království), S. LANGEMEIJER (528 Nizozemské království), J. DROSTE (528 Nizozemské království), D. W. SWINKELS (528 Nizozemské království), A. de SMITH (528 Nizozemské království) a T. de WITTE (528 Nizozemské království, garant)

Vydání

Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2018, 0390-6078

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 7.570

Kód RIV

RIV/00216224:14110/18:00106196

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3324/haematol.2017.171884

UT WoS

000418944500021

Klíčová slova anglicky

myelodysplastic syndromes

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 2. 2019 15:07, Soňa Böhmová

Anotace

V originále

Red blood cell transfusions remain one of the cornerstones in supportive care of lower-risk patients with myelodysplastic syndromes. We hypothesized that patients develop oxidant-mediated tissue injury through the formation of toxic iron species, caused either by red blood cell transfusions or by ineffective erythropoiesis. We analyzed serum samples from 100 lower-risk patients with myelodysplastic syndromes at six-month intervals for transferrin saturation, hepcidin-25, growth differentiation factor 15, soluble transferrin receptor, non-transferrin bound iron and labile plasma iron in order to evaluate temporal changes in iron metabolism and the presence of potentially toxic iron species and their impact on survival. Hepcidin levels were low in 34 patients with ringed sideroblasts compared to 66 patients without. Increases of hepcidin and non-transferrin bound iron levels were visible early in follow-up of all transfusion-dependent patient groups. Hepcidin levels significantly decreased over time in transfusion-independent patients with ringed sideroblasts. Increased soluble transferrin receptor levels in transfusion-independent patients with ringed sideroblasts confirmed the presence of ineffective erythropoiesis and suppression of hepcidin production in these patients. Detectable labile plasma iron levels in combination with high transferrin saturation levels occurred almost exclusively in patients with ringed sideroblasts and all transfusion-dependent patient groups. Detectable labile plasma iron levels in transfusion-dependent patients without ringed sideroblasts were associated with decreased survival. In conclusion, toxic iron species occurred in all transfusion-dependent patients and in transfusion-independent patients with ringed sideroblasts. Labile plasma iron appeared to be a clinically relevant measure for potential iron toxicity and a prognostic factor for survival in transfusion-dependent patients.

Citovat

SWART, L. de, C. REINIERS, T. BAGGULEY, T. van MARREWIJK, D. BOWEN, E. HELLSTROM-LINDBERG, A. TATIC, A. SYMEONIDIS, G. HULS, J. CERMAK, A. A. van de LOOSDRECHT, H. GARELIUS, D. CULLIGAN, M. MACHETA, M. SPANOUDAKIS, P. PANAGIOTIDIS, Marta KREJČÍ, N. BLIJLEVENS, S. LANGEMEIJER, J. DROSTE, D. W. SWINKELS, A. de SMITH a T. de WITTE. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2018, roč. 103, č. 1, s. 69-79. ISSN 0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2017.171884.

@article{1496858,
   author = {Swart, L. de and Reiniers, C. and Bagguley, T. and Marrewijk, T. van and Bowen, D. and HellstromandLindberg, E. and Tatic, A. and Symeonidis, A. and Huls, G. and Cermak, J. and Loosdrecht, A. A. van de and Garelius, H. and Culligan, D. and Macheta, M. and Spanoudakis, M. and Panagiotidis, P. and Krejčí, Marta and Blijlevens, N. and Langemeijer, S. and Droste, J. and Swinkels, D. W. and Smith, A. de and Witte, T. de},
   article_location = {PAVIA},
   article_number = {1},
   doi = {http://dx.doi.org/10.3324/haematol.2017.171884},
   keywords = {myelodysplastic syndromes},
   language = {eng},
   issn = {0390-6078},
   journal = {Haematologica},
   title = {Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes},
   volume = {103},
   year = {2018}
}

TY  - JOUR
ID  - 1496858
AU  - Swart, L. de - Reiniers, C. - Bagguley, T. - Marrewijk, T. van - Bowen, D. - Hellstrom-Lindberg, E. - Tatic, A. - Symeonidis, A. - Huls, G. - Cermak, J. - Loosdrecht, A. A. van de - Garelius, H. - Culligan, D. - Macheta, M. - Spanoudakis, M. - Panagiotidis, P. - Krejčí, Marta - Blijlevens, N. - Langemeijer, S. - Droste, J. - Swinkels, D. W. - Smith, A. de - Witte, T. de
PY  - 2018
TI  - Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes
JF  - Haematologica
VL  - 103
IS  - 1
SP  - 69-79
EP  - 69-79
PB  - FERRATA STORTI FOUNDATION
SN  - 03906078
KW  - myelodysplastic syndromes
N2  - Red blood cell transfusions remain one of the cornerstones in supportive care of lower-risk patients with myelodysplastic syndromes. We hypothesized that patients develop oxidant-mediated tissue injury through the formation of toxic iron species, caused either by red blood cell transfusions or by ineffective erythropoiesis. We analyzed serum samples from 100 lower-risk patients with myelodysplastic syndromes at six-month intervals for transferrin saturation, hepcidin-25, growth differentiation factor 15, soluble transferrin receptor, non-transferrin bound iron and labile plasma iron in order to evaluate temporal changes in iron metabolism and the presence of potentially toxic iron species and their impact on survival. Hepcidin levels were low in 34 patients with ringed sideroblasts compared to 66 patients without. Increases of hepcidin and non-transferrin bound iron levels were visible early in follow-up of all transfusion-dependent patient groups. Hepcidin levels significantly decreased over time in transfusion-independent patients with ringed sideroblasts. Increased soluble transferrin receptor levels in transfusion-independent patients with ringed sideroblasts confirmed the presence of ineffective erythropoiesis and suppression of hepcidin production in these patients. Detectable labile plasma iron levels in combination with high transferrin saturation levels occurred almost exclusively in patients with ringed sideroblasts and all transfusion-dependent patient groups. Detectable labile plasma iron levels in transfusion-dependent patients without ringed sideroblasts were associated with decreased survival. In conclusion, toxic iron species occurred in all transfusion-dependent patients and in transfusion-independent patients with ringed sideroblasts. Labile plasma iron appeared to be a clinically relevant measure for potential iron toxicity and a prognostic factor for survival in transfusion-dependent patients.
ER  -

SWART, L. de, C. REINIERS, T. BAGGULEY, T. van MARREWIJK, D. BOWEN, E. HELLSTROM-LINDBERG, A. TATIC, A. SYMEONIDIS, G. HULS, J. CERMAK, A. A. van de LOOSDRECHT, H. GARELIUS, D. CULLIGAN, M. MACHETA, M. SPANOUDAKIS, P. PANAGIOTIDIS, Marta KREJČÍ, N. BLIJLEVENS, S. LANGEMEIJER, J. DROSTE, D. W. SWINKELS, A. de SMITH a T. de WITTE. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. \textit{Haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2018, roč.~103, č.~1, s.~69-79. ISSN~0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2017.171884.

Podrobný výpis o publikaci